Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung

Current Medical Research and Opinion

Volumn 31, Issue 6, 2015, Pages 1117-1127

  Tjulandin, S ^a   Imyanitov, E ^b   Moiseyenko, V ^c   Ponomarenko, D ^d   Gurina, L ^e   Koroleva, I ^f   Karaseva, V ^g  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c Cancer Centre   (Russian Federation)

^d Regional Oncologic Dispensary   (Russian Federation)

^e Primorsky Krai's Oncological Dispensary   (Russian Federation)

^f Samara Region Clinical Hospital   (Russian Federation)

^g PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Disease management; EGFR mutation; NSCLC; Russian Federation; Therapeutic interventions; Treatment outcomes

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEMCITABINE; PACLITAXEL; EGFR PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; FEMALE; FEMININITY; GENE MUTATION; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RUSSIAN FEDERATION; SMOKING; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RUSSIA;

EID: 84930347422     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1036015     Document Type: Article

References (21)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81
2. Kaprin AD, Starinskiy V, Petrova GV, eds. Malignant neoplasms in Russia in 2012 (morbidity and mortality). Moscow: Russian Ministry of Health, 2014
3. Carrato A, Vergnenègre A, Thomas M, et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin 2014;30:447-61
4. Kaprin AD, Starinskiy V, Petrova GV, eds. Status of cancer care in Russia in 2012. Moscow: Russian Ministry of Health, 2013
5. Vergnenegre A, Corre R, Berard H, et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol 2011;6:161-8
6. Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5):v103-15
7. Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013;121:370-6
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500
11. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11
13. Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adeno-carcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012;18:1947-53
14. Moiseyenko VM, Procenko SA, Levchenko EV, et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie 2010;33:231-8
15. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012;18:2443-51
16. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4): 68-70
17. NCI. Non-Small Cell Lung Cancer Treatment (PDQ). 2014. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/Patient/page1 [Last accessed 28 March 2014]
18. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83: 584-94
19. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005;(2):CD002142
20. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-31
21. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25